Destiny Pharma PLC making significant strides towards phase III evaluation of potential breakthrough C.diff treatment

CEO Neil Clark reported: “We have created important progress due to the fact closing the £10.4mln equity funding in December 2020 that enabled the NTCD-M3 acquisition.”   () main govt Neil Clark reported the group has made important progress planning its direct asset, NTCD-M3, for a phase III clinical review, which […]